351 East Evelyn Avenue
United States - Map
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
|VIVUS Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 7. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 9; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. John L. Slebir Esq.,
Sr. VP and Gen. Counsel
|Mr. Guy P. Marsh ,
VP of U S Operations and Gen. Mang.
|Dr. Wesley W. Day Ph.D.,
VP of Clinical Devel.
|Mr. Michael P. Miller ,
|Mr. Seth H. Z. Fischer ,
Chief Exec. Officer, Chief Commercial Officer and Director
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|